Welcome to our dedicated page for Volitionrx SEC filings (Ticker: VNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
VolitionRx’s SEC filings are packed with pages of nucleosomics data, clinical-trial updates and financing details that can overwhelm even seasoned analysts. Missing a single Form 8-K about a new licensing deal or overlooking insider buying in a Form 4 could distort your view of this diagnostics innovator. Stock Titan’s AI turns those dense disclosures into clear takeaways, so you can focus on the science and the numbers that move VNRX’s valuation.
Our platform ingests every submission to EDGAR the instant it drops and produces plain-English highlights, red-flag alerts and side-by-side comparisons. Whether you’re searching for “VolitionRx quarterly earnings report 10-Q filing” or need “VolitionRx insider trading Form 4 transactions” before market open, we have you covered. Key documents are mapped to the insights they contain:
- 10-K / annual report — cash-burn trends, patent status, and pipeline milestones in one “VolitionRx annual report 10-K simplified” summary.
- 10-Q / quarterly earnings — segment spending, licensing revenue and trial enrollment metrics with concise “VolitionRx earnings report filing analysis”.
- 8-K — real-time alerts on material events; think “VolitionRx 8-K material events explained” minutes after filing.
- Form 4 — “VolitionRx Form 4 insider transactions real-time” so you can track executive stock moves the moment they file.
- DEF 14A proxy — drill into “VolitionRx proxy statement executive compensation” without digging through appendices.
Use Stock Titan’s AI-powered summaries, red-flag detectors and historical sidebars to understand R&D spend, dilution risk and partnership economics—“understanding VolitionRx SEC documents with AI” has never been easier. Schedule custom alerts, export tables for models and compare “VolitionRx executive stock transactions Form 4” against peer trends, all from one screen.
VolitionRx Ltd. reported a Form 4 showing that Nicholas Plummer, General Counsel of Volition Diagnostics, had 8,146 shares of common stock cancelled on
VolitionRx Ltd (VNRX) insider tax-withholding share cancellation
The company reported that on
VolitionRx Ltd. reporting person Jacob Vincent Micallef, Chief Scientific Officer and director, reported a non‑derivative transaction on
Rodney Gerard Rootsaert, a reporting officer and director of VolitionRx Ltd (VNRX), reported a transaction dated 09/28/2025 involving restricted stock units. To satisfy tax withholding on the settlement of 9,900 restricted stock units, VolitionRx retained 4,158 common shares (transaction code F) at an indicated per-share price of $0.605; no open-market sale occurred. After the withholding, the reporting person beneficially owns 145,075 shares directly. In addition, Concord International, Inc. holds 1,007,718 shares indirectly; Rootsaert is a controlling director of Concord and shares voting and dispositive control. The Form 4 indicates shares were retained by the company for tax withholding and clarifies ownership forms but does not show any derivative transactions.
Salvatore Thomas Butera, listed as an officer (CEO - Volition Veterinary) and director of VolitionRx Ltd (VNRX), reported transactions dated 09/28/2025 on a Form 4. The filing shows 5,230 shares of common stock disposed of at $0.605 per share by means of share retention by the issuer to satisfy tax withholding on the settlement of 19,125 restricted stock units; the filing states no shares were sold by the reporting person or the company. The reporting person beneficially owns 332,285 shares following the transaction, and 99,350 shares are jointly owned with his spouse.
Jacob Vincent Micallef, Chief Scientific Officer and director of VolitionRx Ltd (VNRX), reported a Section 16 transaction dated 09/28/2025. The filing shows 5,568 shares of common stock disposed at $0.605 per share under transaction code F. The filer states these shares were retained by VolitionRx to satisfy tax withholding obligations on the settlement of 12,375 restricted stock units, and explicitly notes that no shares were sold by the reporting person or VolitionRx in that transaction.
Following the reported transaction, the reporting person beneficially owns 398,939 shares directly, plus 55,000 shares held indirectly by spouse and 38,113 shares held by Borlaug Limited (the reporting person is the controlling director of Borlaug Limited with voting and dispositive control). The form is a routine insider disclosure of ownership changes related to equity compensation tax withholding.
Ann-Louise Batchelor, Group Chief Marketing Officer of VolitionRx Ltd (VNRX), reported a transaction dated 09/28/2025 on Form 4 in which 5,604 shares of common stock were disposed of under code F at a price of $0.605 per share. The filing shows 154,282 shares beneficially owned directly after the transaction and 29,406 shares indirectly beneficially owned through her spouse.
The filing explanation states these 5,604 shares represent the portion of 11,925 restricted stock units whose shares were retained by VolitionRx and cancelled to satisfy the reporting person’s tax withholding obligations upon settlement. The form clarifies that no shares were sold by the reporting person or by VolitionRx in connection with the withholding.
VolitionRx insider filing: Michel Gaetan, the company's Chief Operating Officer and a director, reported a transaction dated 09/28/2025 reducing his direct common stock holding. The Form 4 shows a Code F disposition of 11,362 shares at $0.605, leaving 369,079 shares beneficially owned directly after the reported transaction. The filing explains these 11,362 shares represent the portion of 22,725 restricted stock units retained by VolitionRx to satisfy tax withholding upon settlement; the form states no shares were sold by the reporting person or the company in the process. The form is signed by Gaetan on 09/30/2025.
Gael Forterre, Chief Commercial Officer and reporting person for VolitionRx Ltd (VNRX), reported a transaction dated 09/28/2025 that reduced his direct common stock holdings by 5,503 shares at a price of $0.605 per share. The filing explains these 5,503 shares were retained by the issuer to satisfy tax withholding obligations upon settlement of 13,725 restricted stock units; no shares were sold by Mr. Forterre or VolitionRx. After the reported transaction he beneficially owns 160,924 shares directly, plus 5,000 shares held by his spouse and 32,500 shares managed by Armorica Partners, LLC, for which he is the managing director and sole shareholder.
Cameron John Reynolds, President and CEO and a director of VolitionRx Ltd (VNRX), reported an open-market purchase of common stock on 09/12/2025. He acquired 15,000 shares at $0.659 per share. After the transaction he directly beneficially owns 2,624,847 shares and indirectly owns 1,007,718 shares through Concord International, Inc.; an additional 34,076 shares are held indirectly by his spouse.
The Form 4 is signed on 09/15/2025. The filing notes Reynolds is majority shareholder of Concord International, Inc., sharing voting and dispositive control over those shares.
FAQ
What is the current stock price of Volitionrx (VNRX)?
What is the market cap of Volitionrx (VNRX)?
